Oragenics,
Inc. (NYSE:MKT - OGEN) today announced that it has launched two new
websites. The first, www.evorapro.com,
is designed to educate dental professionals about the benefits of oral
probiotics in maintaining good oral health and balance, while also
providing information on becoming a partner with Oragenics and offering
its professional strength product, EvoraPro,
in their practices.
The second, www.evoraoralprobiotics.com,
features updated information on Oragenics’ consumer line of oral
probiotics, EvoraPlus
and EvoraPet,
a simpler user interface and a more efficient shopping cart. All of the
Evora products contain ProBiora3, Oragenics’ proprietary blend of three
strains of bacteria specifically composed to naturally freshen breath,
whiten teeth and support overall oral health and balance.
These new websites, along with a refresh of Oragenics’ current corporate
site, www.oragenics.com,
is part of the company’s ongoing efforts to enhance the quality and
availability of information about its organization and products to
dental professionals and consumers worldwide.
New content will continue to roll out on the websites over the coming
months as more features are added to increase functionality.
“The websites are a critical facet of our outreach to the dental
professional community and consumers,” said Dr. John N. Bonfiglio,
President and CEO, Oragenics, Inc. “We are focusing our sales and
marketing efforts on the dental professional and the consumers. These
new websites will aid in the effort to provide the most useful
information and highest quality products possible to our target
audiences, and provide a pleasant shopping experience.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established an exclusive worldwide
channel collaboration for lantibiotics, a novel class of broad spectrum
antibiotics, with Intrexon Corporation Inc., a synthetic biology
company. The collaboration will allow Oragenics access to Intrexon's
proprietary technologies with the idea of accelerating the development
of much needed new antibiotics that will work against resistant strains
of bacteria. Oragenics also develops, markets and sells proprietary
probiotics specifically designed to enhance oral health for humans and
pets, under the brand names Evora
and ProBiora
in over 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond March 31, 2014
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
